ACTOS SUMMARY
ACTOS (pioglitazone hydrochloride) is an oral antidiabetic agent that acts primarily by decreasing insulin resistance. ACTOS is used in the management of type 2 diabetes mellitus (also known as non-insulin-dependent diabetes mellitus [NIDDM] or adult-onset diabetes). Pharmacological studies indicate that ACTOS improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. ACTOS improves glycemic control while reducing circulating insulin levels.
ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes (non-insulin-dependent diabetes mellitus, NIDDM). ACTOS is indicated for monotherapy. ACTOS is also indicated for use in combination with a sulfonylurea, metformin, or insulin when diet and exercise plus the single agent does not result in adequate glycemic control.
Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise. These efforts are important not only in the primary treatment of type 2 diabetes, but also to maintain the efficacy of drug therapy.
|
NEWS HIGHLIGHTSMedia Articles Related to Actos (Pioglitazone)
Health Tip: Signs of Lactose Intolerance
Source: MedicineNet Diarrhea Specialty [2010.01.06]
Title: Health Tip: Signs of Lactose Intolerance
Category: Health News
Created: 1/6/2010 8:10:00 AM
Last Editorial Review: 1/6/2010
Avandia Raises Heart Failure Risk More Than Actos
Source: MedicineNet Diabetic Home Care and Monitoring Specialty [2009.08.19]
Title: Avandia Raises Heart Failure Risk More Than Actos
Category: Health News
Created: 8/19/2009 8:10:00 AM
Last Editorial Review: 8/19/2009
Health Tip: The Lactose-Intolerant Diet
Source: MedicineNet Lactose Intolerance Specialty [2009.07.10]
Title: Health Tip: The Lactose-Intolerant Diet
Category: Health News
Created: 7/10/2009 7:00:00 AM
Last Editorial Review: 7/10/2009
Health Tip: Finding Hidden Lactose
Source: MedicineNet Lactose Intolerance Specialty [2009.04.15]
Title: Health Tip: Finding Hidden Lactose
Category: Health News
Created: 4/15/2009 2:00:00 AM
Last Editorial Review: 4/15/2009
Lactose Tolerance Test
Source: MedicineNet Intestinal Gas (Belching, Bloating, Flatulence) Specialty [2009.04.03]
Title: Lactose Tolerance Test
Category: Procedures and Tests
Created: 11/27/1998 5:08:00 PM
Last Editorial Review: 4/3/2009
Published Studies Related to Actos (Pioglitazone)
Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. [2009.10.14]
Abstract Background: Studies have shown that many patients with type 2 diabetes do not achieve optimal glycemic control, and progression of diabetes over time requires more than one pharmacotherapy to achieve glycemic goal. Objective: To examine the efficacy and safety of the fixed-dose combination (FDC) of pioglitazone 15 mg and metformin 850 mg versus its individual components in a twice-daily regimen over 24 weeks of treatment in type 2 diabetes patients who were currently not receiving antidiabetes therapy...
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. [2009.10]
CONCLUSIONS: Addition of alogliptin to pioglitazone therapy significantly improved glycemic control in patients with type 2 diabetes and was generally well tolerated. The study did not evaluate the effect of combination therapy on long-term clinical outcomes and safety. CLINICAL TRIAL REGISTRATION: NCT00286494, clinicaltrials.gov.
Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. [2009.10]
A 16-week, multicenter, randomized, double blind, parallel-group study was performed to examine whether additional administration of mitiglinide improves glycemic control in Japanese type 2 diabetic patients who are insufficiently controlled by pioglitazone monotherapy... Therefore mitiglinide effectively improves glycemic control in type 2 diabetic patients who are inadequately controlled by pioglitazone monotherapy.
Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia. [2009.09.15]
Context: Patients with congenital adrenal hyperplasia (CAH) are chronically treated with supraphysiological doses of glucocorticoids, which are known to induce insulin resistance... Treatment with pioglitazone improves insulin sensitivity and decreases blood pressure in CAH patients.
CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. [2009.09.10]
Abstract Recent trials of intensive glycaemic control in patients with type 2 diabetes and its impact on cardiovascular disease have led to confusion and speculation amongst physicians. The Action to Control Cardiovascular Risk in Diabetes Study was terminated early because of a significant excess all-cause mortality in the intensively-treated group...
Clinical Trials Related to Actos (Pioglitazone)
A Portion-Controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS [Active, not recruiting]
We hypothesized that a portion controlled diet would prevent the weight gain associated with
the use of a peroxisome profliferator-activated receptor-gamma (PPAR-g). This is a 4 months
randomized clinical trial in type 2 diabetics who are treated with pioglitazone and a
standard diet, pioglitazone and a portion-controlled diet and metformin with a standard
diet.
Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan pioglitazone HCl
45 mg tablets to Takeda Actos® 45 mg tablets following a single, oral 45 mg (1 x 45 mg) dose
administration under fasting conditions.
Food Study of Pioglitazone HCl Tablets 45 mg to Actos® Tablets 45 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan pioglitazone HCl
45 mg tablets to Takeda Actos® 45 mg tablets following a single, oral 45 mg (1 x 45 mg) dose
administration under fed conditions.
A Study to Evaluate SYR-322 Plus Pioglitazone HCl (Actos®), SYR-322 Alone, or Pioglitazone HCl Alone for the Treatment of Type 2 Diabetes [Active, not recruiting]
This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and
safety of SYR-322 plus pioglitazone HCl, SYR-322 alone, or pioglitazone alone in subjects
with type 2 diabetes.
Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation (PERISCOPE) [Completed]
|
